Legislation that cleared the US House 4 February would support a drug supply chain "elasticity" pilot project to show how critical supplies could expand when demand soars like it has with the COVID-19 pandemic, and then shrink back afterward. While the initiative is designated as a pilot, it would receive significant funding: $1.5bn.
Enhancing this kind of flexiblity is a big riddle that next-pandemic planners will have to solve. (Also see "Consortium...